Deducting indications for SIRT treatment in GIST patients, the best result can be expected in patients without known activating mutations in KIT or PDGFRα with a median of 25 months of H-PFS not offered by any other treatment option. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.